Article PDF
Avoid common mistakes on your manuscript.
References and Recommended Reading
Jensen PS: Introduction ADHD Comorbidity and treatment outcomes in the MTA. J Am Acad Child Adolesc Psychiatry 2001, 40:134.
Special Issue: Child and family characteristics as predictors and outcomes in the Multimodal Treatment Study of ADHD (MTA Study). J Abnorm Child Psychol. 2000, 28:6.
The MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder (ADHD). Arch Gen Psychiatry 1999, 56:1073–1086.
The MTA Cooperative Group: Moderators and mediators of treatment response for children with ADHD: the MTA. Arch Gen Psychiatry 1999, 56:1088–1096.
Conners CK, Epstein JN, March JS, et al.: Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. J Amer Acad Child Adolesc Psychiatry 2001, 40:159.
Swanson M, Kraemer HC, Hinshaw SP, et al.: Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Amer Academy Child Adolesc Psychiatry 2001, 40:168.
March JS, Swanson JM, Arnold LE, et al.: Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD. J Abnorm Child Psychol 2000, 6:527–541.
Jensen PS, Hinshaw SP, Kraemer HC, et al.: ADHD comorbidity findings from the MTA study: comparing comorbid subtypes. J Am Acad Child Adolesc Psychiatry. 2001, 40: in press.
Newcorn JH, Halperin JM, Jensen PS, et al.: Symptom profiles in children with ADHD: effects of comorbidity and gender. J Am Acad Child Adolesc Psychiatry 2001, 40:137.
Pelham WE, Gnagy EM, Greiner AR, for the MTA Cooperative Group: Parent and teacher satisfaction with treatment and evaluation of effectiveness. Presented at the Annual Meeting of the Association for the Advancement of Behavior Therapy. New Orleans, LA; November, 2000.
Arnold LE, Severe J, Kraemer H, et al., for the MTA Cooperative Group: Differential enduring effects of MTA treatments at 24 months. Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York, NY; October 24–29, 2000:66.
Hoagwood K, Jensen P, Wigal T, et al., for the MTA Cooperative Group: Impact of ADHD treatments on subsequent use of services. Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York, NY; October 24–29, 2000.
Greenhill LL, for the Concerta Study Group: Development of New Long-Duration Stimulant for ADHD: Alza’s Concerta. Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York, NY; October 24–29, 2000:87.
Pelham WE, Gnagy EM, Burrows-Maclean L, et al.: Once-a-day Concerta methylphenidate vs tid methylphenidate in laboratory and natural settings. Pediatrics. 2001, in press.
Swanson J, Spencer T, Markabi S, et al.: A new modified-release formulation of Ritalin in children with ADHD. Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York, NY; October 24–29, 2000:87.
Greenhill LL, for the Concerta Study Group: Subtypes of ADHD: differentiated by response to methylphenidate? Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York, NY; October 24–29, 2000:116.
Wilens T: Long-term efficacy and safety of Concerta (Oros - Methylphenidate Hcl) extended release tablets. Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York, NY; October 24–29, 2000:87.
Swanson J, James M: Development and clinical trial testing of Concerta for the treatment of ADHD in children. Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York, NY; October 24–29, 2000:34.
Spencer T, Swanson J, Markabi S, et al.: Pharmacodynamic and pharmacokinetic profiles of a new modified-release formulation of methylphenidate in children with ADHD [Poster abstracts]. 40th Annual NCDEU Meeting. May, 2000:158.
Greenhill LL, for the MPH MR ADHD Study Group: Once daily, methylphenidate modified release (MPH MR) treatment of attention-deficit/hyperactivity disorder (ADHD). Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York, NY; October 24–29, 2000:116.
McCracken J, Biederman J, Greenhill L, et al.: Analog classroom assessment of SL138 for treatment of ADHD. Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York, NY; October 24–29, 2000:104.
McGough JJ, Greenhill L, Biederman J, et al.: PK/PD analyses of SL1381 in pediatric ADHD. ScientificProceeding of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York, NY; October 24–29, 2000:117.
Biederman J, Baldessarini RJ, Wright V, et al.: A double-blind placebo-controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 1989, 28:777–784.
Heiligenstein JH, Spenser TJ, Faries DE, et al.: Efficacy of tomoxetine vs placebo in pediatric outpatients with ADHD. Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York, NY; October 24–29, 2000:101.
Conners CK, Casat CD, Gualtieri CT, et al.: Bupropion hydorchloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996, 35:1314–1321.
Swanson J, Sale M, Webster C, et al.: Pediatric pharmacokinetics/pharmacodynamics of GW320659 in attentiondeficit/ hyperactivity disorder (ADHD). Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York, NY; October 24–29, 2000:114.
DeVeaugh-Geiss J, Conners CK, Sarkis E, et al.: Efficacy of GW320659 in children with attention-deficit/hyperactivity disorder. Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York, NY; October 24–29, 2000:115.
Scahill L, Chappell PB, Kim YS, et al.: Guanfacine in the treatment of children with tic disorders and ADHD: a placebo-controlled study [Poster abstracts]. 40th Annual NCDEU Meeting. Boca Raton, FL; May 30–June 2, 2000:69.
Horrigan JP, Barnhill LJ: The long-term efficacy and safety of guanfacine in child psychiatry. Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York, NY; October 24–29, 2000:97.
Kotler L, Findling R, Fried J, et al.: An open label study of venlafaxine in children and adolescents with ADHD. Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York, NY; October 24–29, 2000:117.
Garfinkel BD, Wender PH, Sloman L, O’Neill I: Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. J Am Acad Child Psychiatry 1983, 22:343–348.
Hudziak J, Brigidi B, Marte B, et al.: Bupropion SR in the treatment of stimulant-responsive ADHD adolescents. Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York, NY; October 24–29, 2000:117.
Carlson GA, Loney J, Salisbury H, et al.: Stimulant treatment in young boys with symptoms suggesting juvenile mania: a report from a longitudinal study. The Scientific Proceedings of the New Clinical Drug Evaluation Unit (NCDEU). May, 2000:62.
Carlson GA, Loney J, Salisbury H, et al.: Stimulant treatment in young boys with symptoms suggesting childhood mania: a report from a longitudinal study. J Child Adolesc Psychopharmacol 2000, 10:175–184.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Newcorn, J.H. New treatments and approaches for attention deficit hyperactivity disorder. Curr Psychiatry Rep 3, 87–91 (2001). https://doi.org/10.1007/s11920-001-0004-3
Issue Date:
DOI: https://doi.org/10.1007/s11920-001-0004-3